Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Development programme

SELECT — semaglutide cardiovascular outcomes without diabetes

An event-driven cardiovascular outcome trial in adults with overweight or obesity and established cardiovascular disease but without diabetes. The Institute treats SELECT as the single most consequential trial in this compound class because it separates the cardiovascular effect from glycaemic control.

An event-driven cardiovascular outcome trial in adults with overweight or obesity and established cardiovascular disease but without diabetes. The Institute treats SELECT as the single most consequential trial in this compound class because it separates the cardiovascular effect from glycaemic control.

Sponsor class: Manufacturer-sponsored. First record: 2018.

Showing 0 records on this page

Records in this programme

2 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
SELECTSemaglutidePhase 3ReportedEvent-driven cardiovascular outcome trial17,6042023High
SELECT-ADHERENCEprogramme recordSemaglutidePhase 3ReportedObservational—2023Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.